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SUMMARY
Background
Iron deficiency is a common and undertreated problem in inflammatory bowel dis-
ease (IBD).
Aim
To develop an online tool to support treatment choice at the patient-specific level.
Methods
Using the RAND/UCLA Appropriateness Method (RUAM), a European expert
panel assessed the appropriateness of treatment regimens for a variety of clinical
scenarios in patients with non-anaemic iron deficiency (NAID) and iron deficiency
anaemia (IDA). Treatment options included adjustment of IBD medication only,
oral iron supplementation, high-/low-dose intravenous (IV) regimens, IV iron plus
erythropoietin-stimulating agent (ESA), and blood transfusion. The panel process
consisted of two individual rating rounds (1148 treatment indications; 9-point
scale) and three plenary discussion meetings.
Results
The panel reached agreement on 71% of treatment indications. ‘No treatment’ was
never considered appropriate, and repeat treatment after previous failure was gen-
erally discouraged. For 98% of scenarios, at least one treatment was appropriate.
Adjustment of IBD medication was deemed appropriate in all patients with active
disease. Use of oral iron was mainly considered an option in NAID and mildly
anaemic patients without disease activity. IV regimens were often judged appropri-
ate, with high-dose IV iron being the preferred option in 77% of IDA scenarios.
Blood transfusion and IV+ESA were indicated in exceptional cases only.
Conclusions
The RUAM revealed high agreement amongst experts on the management of iron
deficiency in patients with IBD. High-dose IV iron was more often considered
appropriate than other options. To facilitate dissemination of the recom-
mendations, panel outcomes were embedded in an online tool, accessible via
http://ferroscope.com/.
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INTRODUCTION
Iron deficiency is a common condition in patients with
inflammatory bowel disease (IBD) and may be caused by
intestinal blood loss, reduced duodeno-jejunal iron
absorption and/or dietary restrictions.1 Prevalence data
range from 36% to 90%, depending on the study popula-
tion and definitions used.2 Iron deficiency is one of the
major causes of anaemia in IBD (iron deficiency anae-
mia; IDA), having a significant impact on the patient’s
quality of life.3, 4 This impact is not only seen in patients
with clinical symptoms of anaemia, but could also be
‘hidden’ in slowly deteriorating physical and cognitive
function, often not readily recognised by patients and
their physicians.5, 6 Several studies have shown that cor-
recting iron deficiency in IBD positively affects the
patient’s quality of life.3, 4, 7 Evidence from other disease
areas supports this beneficial impact to be also present
in patients with non-anaemic iron deficiency (NAID).8, 9
There are various treatment options available for correct-
ing iron deficiency and anaemia and many new formula-
tions have been introduced over the last few years. These
include oral iron supplementation and intravenous (IV)
regimens, the latter in low or high doses. For selected
patient groups, other regimens may be considered as
well, such as adjustment of IBD medication, addition of
an erythropoietin-stimulating agent to IV iron (IV+ESA),
and blood transfusion. Treatment choice requires care-
fully balancing the benefits and negative consequences of
the available treatments in relation to specific patient
conditions such as the presence of symptoms, IBD dis-
ease activity and haemoglobin levels.1 It is also important
to take into consideration that anaemia in IBD may be
caused by other factors besides iron deficiency. Inflam-
mation-induced changes to the iron metabolism and
erythropoiesis form the second important cause of anae-
mia in IBD (anaemia of chronic disease; ACD). Other
less common causes are cobalamin and folate deficiency
and use of particular drugs.1 IDA and ACD are fre-
quently overlapping conditions. Distinguishing between
the causes of anaemia in IBD is important from a thera-
peutic perspective: iron supplementation may be unnec-
essary or even counterproductive in pure ACD, while it
is mostly necessary in IDA.10, 11 Paradoxically, despite
their high prevalence in IBD, anaemia and iron defi-
ciency are believed to be underdiagnosed, neglected as a
clinical problem and often undertreated.2 This could
partly be ascribed to the lack of or slow development of
clinical symptoms, but has also been attributed to a low
awareness amongst gastroenterologists because they are
‘commonly exposed to severe blood loss and low haemo-
globin levels’.1
To support adequate management of iron deficiency
and anaemia in IBD, Gasche et al. developed a guideline
specifically dedicated to this topic.1 In addition, recom-
mendations and treatment algorithms have been
included in guidelines on IBD12–14 and IDA15, and also
in some review articles.16, 17 All guidelines and recom-
mendations express the need of increased attention,
timely diagnosis and appropriate treatment choice, but
differ in their level of specificity, scope and views on the
mode of administration. To streamline the available evi-
dence in the light of the heterogeneity of IBD patients, a
European group of gastroenterologists initiated a project
to develop recommendations on the treatment of NAID/
IDA in IBD at the patient-specific level, and to make
these recommendations available to practising physicians
via an online decision support tool.
METHODS
Study design
To develop treatment recommendations at the
patient-specific level, we used the RAND/UCLA Appro-
priateness Method (RUAM).18–20 This modified Delphi
method has been widely applied to determine the appro-
priateness of medical and surgical procedures in various
fields of medicine, including several aspects of the man-
agement of IBD.21–24 The RUAM provides a structured
approach to combine best evidence from clinical studies
with the collective judgments of a panel of experts. Sev-
eral studies have shown that the RUAM produces reli-
able, internally consistent and clinically valid
results.20, 25–29 The study design is depicted in Figure 1.
Panel composition
The panel consisted of 16 gastroenterologists from 16
European countries, and a (nonvoting) expert in iron
deficiency and anaemia (GW). Selection of the panel
members was done by the panel chair (WR) on the basis
of their clinical and scientific expertise in the field of
IBD, and geographical spread to allow a European view
on the topic. The panel was supported by a methodolo-
gist experienced in the RUAM (HS).
Literature study
A comprehensive literature study was conducted by a
methodologist experienced in the RUAM to serve two
purposes. First, the results were used to shape the
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research question and to determine the study design.
Secondly, a comprehensive overview of clinical studies
was provided as unbiased as possible to the panellists,
ensuring that they had access to the same body of evi-
dence while doing the appropriateness assessments (see
Data S1). In addition, the first author performed inde-
pendently an in-depth review on the topic of iron defi-
ciency in IBD.30
Panel process and rating structure
During the first panel meeting (October 2011), the
results of the literature research were discussed, extended
and refined. The final results were included in the elec-
tronic rating tool as look-up materials (see Data S1).
Furthermore, the starting points of the study were deter-
mined.
The study population was defined as patients with
IBD (newly diagnosed, or at any follow-up), having bio-
chemical evidence of iron deficiency, with or without
physical signs and symptoms. Patients with conditions
likely to be the primary cause of anaemia, other than
iron deficiency and ACD, were excluded from the con-
siderations; additional exclusion criteria were age
<18 years, pregnancy and presence of absolute con-
tra-indications for any of the treatments included.
Because of the presumed difference in therapeutic
approach, the patient population was split into two
groups according to the presence of anaemia: NAID and
IDA. Selected treatment options for NAID included no
active treatment, oral iron, and IV regimens (low/high
dose; cut-off point 500 mg iron per single infusion). For
IDA, the combination of an IV regimen plus ESA was
added to the therapeutic arsenal. For both NAID and
IDA, the panel selected a set of clinical variables consid-
ered relevant to treatment choice, such as previous treat-
ment of iron deficiency, and symptoms and conditions
related to iron deficiency and anaemia. By permutation,
a set of 56 different scenarios was constructed for NAID,
and 112 scenarios for IDA. Panellists used an electronic
rating program to individually assess the appropriateness
of treatments for all scenarios on a 9-point scale (refer-
ence values: 1 = inappropriate, 5 = uncertain,
9 = appropriate). They were instructed to consider only
the clinical perspective and to disregard financial costs
and other potential constraints to the availability of
treatments. During a plenary meeting (March 2012), the
Figure 1 | Study design.
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results of the first rating round were discussed. The dis-
cussion revealed some differences in the interpretation of
the definitions and clinical scenarios, and also in the way
the appropriateness of treatments had been rated. In
addition, the panel concluded that particular treatment
options were missing. Subsequently, a second individual
rating round took place, using an adapted structure and
refined definitions and instructions. This round included
the assessment of 1148 indications spread over 196 clini-
cal scenarios. An overview of clinical variables and treat-
ment options is provided in Table 1. Based on the
second round results, a prototype of an electronic deci-
sion support tool was developed. During a third panel
meeting (October 2012), final recommendations and
adaptations to the tool were established.
Statistical analysis
The translation of individual ratings to panel statements
was based on the mathematical rules that are typically
applied in RUAM studies.19 The panel was said to have
agreement if at least 12 out of the 16 ratings were in the
same section of the 9-point scale (1–3, 4–6 or 7–9). Dis-
agreement was defined as the situation in which at least
5 panellists scored in each of the sections 1–3 and 7–9.
An indication was deemed appropriate if the median
panel score was between 7 and 9, and inappropriate if
the median was between 1 and 3, both without disagree-
ment. All other outcomes were labelled ‘uncertain’.
Frequency tables and cross-tabulations were used to
describe and analyse the appropriateness of treatments
in relation to patient conditions.
RESULTS
Agreement
Overall, agreement increased from 43% in the first round
to 71% in the second round. Disagreement (12% after
the second round) was largely explained by different
views on the use of low-dose IV iron in patients with
IDA.
Appropriateness
Appropriateness figures after the second round are sum-
marised in Table 2.
Providing no treatment was almost always deemed
inappropriate. For both NAID and IDA, IV iron was the
treatment option most frequently considered appropriate,
with high-dose IV iron being the preferred option in
77% of IDA scenarios. For almost all scenarios (98%),
there was at least one appropriate option available, while
exactly one appropriate option existed for 83% of scenar-
ios.
Factors determining the appropriateness of treatment
Cross-tabulations showed that previous treatment was
the most discriminative factor for the appropriateness
outcomes, followed by IBD activity status for NAID, and
Table 1 | Overview of variables and treatment options
used for the construction of clinical scenarios in the
second rating round (for details: see appendix 1)
NAID IDA
Variables
Previous treatment of iron deficiency X X
Haemoglobin level X
Physical symptoms of iron depletion X
Conditions associated with
additional iron need
X X
IBD activity status X X
Treatment options
None X X
Adjusting IBD medication only X
Oral iron X X
Low-dose IV iron X X
High-dose IV iron X X
IV iron + ESA X
Blood transfusion X
IBD, inflammatory bowel disease; IV, intravenous; ESA, eryth-
ropoietin-stimulating agent; NAID, non-anaemic iron defi-
ciency; IDA, iron deficiency anaemia.
Table 2 | Appropriateness figures (%) after the
second round (sum of row totals is 100%)
Treatment Inappropriate Uncertain Appropriate
Non-anaemic iron deficiency
None 96 4 0
Adjustment IBD
medication
50 0 50
Oral iron 71 18 11
Low-dose IV iron 43 29 29
High-dose IV iron 0 32 68
Iron deficiency anaemia
None 100 0 0
Oral iron 87 12 1
Low-dose IV iron 43 50 7
High-dose IV iron 1 14 86
IV iron + ESA 82 5 14
Blood transfusion 77 21 1
IBD, inflammatory bowel disease; IV, intravenous; ESA, eryth-
ropoietin-stimulating agent.
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haemoglobin level for IDA. Recommendations by princi-
pal variables are summarised in Figure 2 for NAID. A
distinction was made between appropriate and optional,
the latter consisting of indications for which the outcome
was uncertain for most cases, or appropriate in only very
specific subgroups. Oral iron was considered appropriate
in inactive disease if there was no previous treatment or
if oral iron had been successful in the past. IBD activity
status (inactive/active) showed a clear-cut outcome for
the adjustment of IBD medication only. In patients with
active disease, this treatment option was always appro-
priate, while being inappropriate in those with inactive
disease. Low-dose IV iron was deemed appropriate if
previous use had been successful, and also after failure of
oral treatment. High-dose IV iron was considered appro-
priate for the majority of NAID cases, even if previous
use had not been successful.
Summarised recommendations for IDA are provided
in Figure 3. High-dose IV iron was almost always con-
sidered an appropriate treatment, except when it had
previously failed. In those cases, IV iron + ESA was the
preferred option. Low-dose IV iron was judged appropri-
ate if it had successfully been used in the past. Blood
transfusion was usually deemed inappropriate, but the
outcomes indicate that it could be an option in selected
patients with a haemoglobin level below 8 g/dl, for
example, in those having physical symptoms of anaemia.
Online decision support tool
Figures 2 and 3 cover the global panel outcomes in rela-
tion to the most important clinical variables. However,
for a number of indications, the appropriateness patterns
were more complex, and full representation is almost
impossible in a paper form. Therefore, data were embed-
ded in an online decision support tool that allows the
user to select a patient profile and to view the appropri-
ateness of treatments for that profile, including the panel
considerations behind the outcomes (Figure 4). Similar
tools have been developed for other topics related to the
management of IBD.21, 22, 24 The program can be
accessed via http://ferroscope.com/.
DISCUSSION
It is increasingly recognised that iron deficiency and IDA
are underdiagnosed and undertreated conditions in
patients with IBD.2, 31, 32 This has been attributed not
only to a lack of awareness about the impact of these
conditions on quality of life1, but also to common
Figure 2 | Summarised recommendations for NAID by previous treatment and IBD activity status. Appropriate
treatments are displayed in green, optional treatments (uncertain or appropriate in specific situations) in yellow. IBD
activity status: I = inactive, A = active; IBD-med: adjustment of IBD medication only; IV: intravenous.
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misconceptions about their prevalence, and about the
efficacy and safety of the available iron supplementation
regimens.2 In addition, the heterogeneity and complexity
of iron deficiency and anaemia in IBD patients necessi-
tate a tailored approach in relation to relevant patient
characteristics.1 The RUAM proved to be useful in
exploring the appropriateness of treatments for a variety
of clinical scenarios and in producing recommendations
at the patient-specific level.
The expert panel reached high agreement on the
appropriateness of 1148 treatment indications spread
over 196 clinical scenarios. The panel results were both
comprehensive and specific. In 98% of scenarios, there
was at least one treatment option considered appropriate,
and in 83%, this concerned exclusively one of the treat-
ments.
The RUAM focused on classes of formulations as oral,
low-dose IV and high-dose IV iron instead of specific
compounds. Oral iron treatments may have some slight
pharmacokinetics differences depending on the iron salt
used, the iron content or the combinations with additives
such as ascorbic acid. However, there are no reliable evi-
dence-based data comparing different oral preparations
so far. The same applies within the classes of low-dose
and high-dose iron formulations. In addition, available IV
iron formulations have a similarly excellent safety profile
with an extremely low risk for serious adverse events.30
For both NAID and IDA, ‘no treatment’ was generally
considered inappropriate. Current guidelines and recom-
mendations also stress that treatment should be consid-
ered for all patients with IDA1, 12, 14, but are not or less
explicit for treatment initiation in NAID. The guidelines
provided by Gasche et al. mention that the decision on
iron supplementation in NAID is more complicated and
that different approaches should be considered.1 Accord-
ing to the algorithm developed by Munoz et al., iron
supplementation is also recommended in patients with
NAID.16 Adjustment of IBD treatment only (thus with-
out iron supplementation) was considered in our study
only as a treatment option for patients with NAID. The
outcomes here were clear-cut, recommending this as an
appropriate option in all patients with active disease.
Scenarios for which oral iron was considered appropriate
were primarily related to NAID. In IDA, it is an appro-
Figure 3 | Summarised recommendations for IDA by previous treatment and haemoglobin level. Appropriate
treatments are displayed in green, optional treatments (uncertain or appropriate in specific situations) in yellow. Hb:
haemoglobin level; IV: intravenous.
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priate option in patients after previously successful oral
treatment, but not if the haemoglobin level is less than
10 g/dl. For most indications, IV iron was recom-
mended. This is in line with the guideline by Gasche
et al. who stated that IV iron is the preferred route of
supplementation, although many patients respond to oral
iron.1 The rationale behind this statement is the often
higher efficacy and better tolerance of IV regimens in
IBD.1 The IBD guideline of the British Society of Gastro-
enterology takes a different perspective, mentioning that
oral supplementation can be used as an initial therapy,
and that IV regimens are preferred in patients with poor
tolerance to oral iron.14 This does not take into account
that dietary iron absorption is negatively affected by
inflammation via the action of cytokines and the iron
regulatory peptide hepcidin,10, 11, 33 suggesting that oral
iron is less absorbed in IBD patients with inflammatory
activity. The algorithm of Munoz et al. follows this
approach, but advices immediate IV iron in patients with
a haemoglobin level <10 g/dL.16
In our study, high-dose IV iron (>500 mg iron per
single infusion) was more often judged appropriate than
lower doses (68% vs. 29% in NAID; 86% vs. 7% in
IDA). In the FERGICOR study, which compared two
different treatment strategies including a low-dose IV
iron sucrose (IS) and high-dose IV ferric carboxymaltose
(FC) arm in patients with IBD, a superior cost-effective-
ness of high-dose IV was suggested.34 More infusions
were required in the IS group and total treatment costs
for FC over the whole study period were lower.34 A ret-
rospective study from Denmark also suggested that FC
was more cost-effective as compared with IS due to
fewer out-patient visits. The corresponding Budget
Impact Analysis from a hospital perspective showed that
Figure 4 | User interface of the online decision support tool. An example of a patient profile is highlighted in blue at
the left side. The appropriateness of treatment options under consideration is visualised by colour codes at the right
side. Panel considerations (for high-dose IV iron in this example) are available by clicking on ‘details’.
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FC was more expensive.35 The collective ratings from the
panel obviously share the opinion that regimens that
allow administration of the full dose at one time or in
few sessions only are much more convenient to the
patient, by preventing repeat visits and avoiding
disturbance of activities of daily life. However, as in
almost all RUAM studies, costs of treatment were not
taken into consideration and the panel did not weigh the
usually higher costs of high-dose IV iron regimens vs.
their benefits for the patient and reduced healthcare util-
isation.
The panel reserved IV iron + ESA predominantly for
patients insufficiently responding to high-dose IV iron
which is in accordance with the Gasche guideline.1 How-
ever, such patients may need a careful re-evaluation to
rule out other causes for anaemia or nonresponse to IV
iron.36, 37 Adequate diagnosis and treatment of iron defi-
ciency should avoid blood transfusion1, and only few
scenarios existed for which the panel deemed this to be
an appropriate option. These concerned specific cases of
anaemia with a haemoglobin level <8 g/dL.
The specificity of the panel outcomes in relation to
relevant patient characteristics asked for a manageable
format to disseminate the information. For that purpose,
the panel recommendations are made available to prac-
tising physicians via an online tool that allows a quick
‘second opinion’ on the appropriateness of treatment for
any given patient.
The applicability of the patient-specific recommenda-
tions in clinical practice is an important strength of the
approach used in this study. However, we have to take
into account that the panel recommendations are based
on theoretical profiles; therefore, the validity of the
online tool needs to be determined in prospective stud-
ies. In general, we feel that this tool may help increase
the awareness of the importance of a timely diagnosis
and appropriate treatment of iron deficiency in IBD.
CONCLUSIONS
The RUAM was useful in establishing recommendations
on the treatment of iron deficiency in patients with IBD.
Iron supplementation was deemed necessary in almost
all patients with either NAID or IDA. (High-dose) IV
iron was more often considered appropriate than other
options. The online tool may help disseminate the rec-
ommendations and increase awareness on the impor-
tance of treatment of iron deficiency in IBD.
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APPENDIX 1: DEFINITIONS USED
NON-ANAEMIC IRON DEFICIENCY (NAID)
-Biochemical evidence of iron deficiency and normal haemoglobin level
-Iron deficiency: ferritin level <30 ng/ml in inactive disease, <100 ng/ml in active disease
-Normal haemoglobin: men ≥ 13 g/dl, non-pregnant women ≥ 12 g/dl (WHO definition)
IRON DEFICIENCY ANAEMIA (IDA)
-Anaemia with biochemical evidence of iron deficiency
-Anaemia: men <13 g/dl, non-pregnant women <12 g/dl (WHO definition)
-Iron deficiency: ferritin level <30 ng/ml in inactive disease, <100 ng/ml in active disease
(PREVIOUS) TREATMENTS
-Oral iron supplementation: optimised regimen according to the physician’s judgment
-Low-dose IV iron supplementation (per single infusion): iron doses less than 500 mg
-High-dose IV iron supplementation (per single infusion): iron doses of 500 mg or more
-Previous treatment and outcome relate to a similar situation (profile)
-Insufficient response: reference point: serum ferritin <100 ng/ml, 6-8 weeks after treatment initiation
-Intolerance: unacceptable side effects
-Previous treatment with IV iron: in case of failure of IV iron it is assumed that oral treatment has also failed
-Blood transfusion: optimal regimen according to the physician’s judgment
CONDITIONS ASSOCIATED WITH ADDITIONAL IRON NEED
-For example: menstruation, history of anaemic episodes, previous gastrointestinal surgery
PHYSICAL SYMPTOMS OF IRON DEPLETION
-Symptoms (e.g. fatigue, shortness of breath) having a significant impact on quality of life.
IBD ACTIVITY STATUS
-Definition active disease: evidence of inflammation based upon biochemical parameters, clinical symptoms and/or
diagnostic imaging.
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